InMed Pharmaceuticals Confirms INM-901 Oral Formulation for Alzheimer's Treatment
InMed Pharmaceuticals announces confirmation of INM-901 oral formulation for Alzheimer's treatment, showcasing potential breakthrough in cannabinoid-based pharmaceutical drugs.
This news matters as it highlights a potential breakthrough in the treatment of Alzheimer's disease, offering hope for new treatment alternatives to patients. The confirmation of INM-901 as an oral formulation with similar drug levels in the brain tissue compared to intraperitoneal delivery could significantly impact the development of cannabinoid-based pharmaceutical drugs.
